首页> 外文OA文献 >Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

【2h】

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

机译：I阶段研究Rucaparib与卵巢癌患者的Bevacizumab组合：最大耐受剂量和药代动力学曲线

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Domenica Lorusso; Giuseppa Maltese; Ilaria Sabatucci; Sara Cresta; Cristina Matteo; Tommaso Ceruti; Maurizio D’Incalci; Massimo Zucchetti; Francesco Raspagliesi; Cristina Sonetto; Valentina Sinno; Dominique Ronzulli; Serena Giolitto; Filippo de Braud;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer [J] . Soria Jean-Charles, Adjei Alex A., Bahleda Rastilav, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：IB剂量 - 升级对PictIlaxel和Carboplatin（有或没有Bevacizumab）或Pemetroxed和顺铂（有或没有或没有或没有Bevacizumab）的患者的安全和药代动力学的升级研究
2. 949 POSTER Antiangiogenesis as new treatment modality in ovarian cancer: a phase Ib, open label, safety and pharmacokinetics (PK) study of escalating doses of PTK787/ZK222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (pts) with stage IC to IV epithelial ovarian cancer [J] . European Journal of Cancer Supplements . 2005,第2期

机译：949 POSTER抗血管生成作为卵巢癌的新治疗方法：Ib期，开放标签，安全性和药代动力学（PK）研究，逐步增加PTK787 / ZK222584（PTK / ZK）剂量与紫杉醇和卡铂联合治疗在分期患者中的作用IC至IV上皮性卵巢癌
3. Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant. [J] . Hiemenz J, Cagnoni P, Simpson D, Antimicrobial agents and chemotherapy. . 2005,第4期

机译：米卡芬净联合氟康唑与氟康唑单独应用的药代动力学和最大耐受剂量研究，用于预防接受骨髓或外周干细胞移植的成年患者的真菌感染。
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. A robust paradigm of finding the maximum tolerated dose in Phase I cancer clinical trials with application to IL-21 denenicokin [D] . Young, Tina Chang. 2017

机译：在I期临床研究中将最大耐受剂量应用于IL-21 Denenicokin的最大范例
6. Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant [O] . J. Hiemenz, P. Cagnoni, D. Simpson, 2005

机译：米卡芬净联合氟康唑和氟康唑单独应用对预防骨髓或外周干细胞移植的成年患者真菌感染的药代动力学和最大耐受剂量研究
7. Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results [O] . Jermaine I. Coward, Minal A. Barve, Ganessan Kichenadasse, 2021

机译：腹膜内癌症，持续性或复发性卵巢癌，输卵管癌症或原发性腹膜癌患者的最大耐受剂量和抗肿瘤活性：阶段研究结果

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

著录项

引文网络

相似文献

相关主题

期刊订阅